Iomab-B
Iomab-B is Actinium's radioactive antibody that clears the bone marrow before a transplant for older patients with active relapsed acute myeloid leukaemia; the phase 3 SIERRA trial met its primary endpoint but the FDA asked for another study.
Overview
Iomab-B delivers iodine-131 to CD45-positive cells, allowing patients with relapsed or refractory acute myeloid leukaemia who would not tolerate conventional myeloablative conditioning to proceed to allogeneic transplant. In the phase 3 SIERRA trial, Iomab-B followed by transplant produced durable complete remission at six months in a substantially higher share of patients than conventional care. Actinium reported in 2024 that the FDA requested an additional randomised trial before filing, and it is seeking partners; the trial is recorded here.
- Chelated Lu-177 / Ac-225
- Antigen-positive cell
- Radiation, not chemistry
An antibody against CD45, found on all white blood cells, carries iodine-131 to the marrow and leukaemia cells and ablates them in place of high-dose chemotherapy before a stem cell transplant.
- PSMA / SSTR-positive cell
1.Iomab-B binds its target.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"Iomab-B" OR ABSTRACT:"Iomab-B" OR TITLE:"Apamistamab-I131" OR ABSTRACT:"Apamistamab-I131" OR TITLE:"131I-apamistamab" OR ABSTRACT:"131I-apamistamab") AND (radiopharmaceutical OR radioligand OR radionuclide OR theranostic OR "nuclear medicine" OR "molecular imaging" OR radiotracer OR scintigraphy OR cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Iomab-B, not a curated reading list.
Similar pages
not linked directly; found by shared links- TrialStudy of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
Shares Iodine-131 and the tag pipeline.
- JournalCancer biotherapy & radiopharmaceuticals
Shares Radio-antibody & radio-ADC, Radioligand therapy (beta emitters).
- CompanyAbdera Therapeutics
Shares Radio-antibody & radio-ADC, Radioligand therapy (beta emitters).
- PersonKatherine K. Matthay
- AgentIodine-131 tositumomab
Shares Radio-antibody & radio-ADC, Iodine-131.
- IdeaA coordinated reserve and shared schedule for the world's medical isotope reactors
- IdeaPretargeted alpha radioimmunotherapy
Shares Radio-antibody & radio-ADC, Iodine-131.
- Key paperRadiopharmaceutical therapy in cancer: clinical advances and challenges